Inogen's Q1 Revenue Jumps 3.4% to Beat Estimates, Driven by International Demand
INGN sits 32% above its 52-week low of $5.34.
Summary
Inogen reported first-quarter revenue of $85.10 million, a 3.4% year-over-year increase, exceeding analyst estimates of $82.35 million. The company also surpassed adjusted net income expectations, reporting -$4 million against a -$7.70 million consensus, primarily driven by strong international demand for its portable oxygen concentrators. While adjusted EBITDA slightly missed estimates at -$1.40 million, the company reiterated its full-year 2026 revenue guidance of $366 million to $373 million and its commitment to improving adjusted EBITDA. This mixed earnings report indicates continued top-line growth, particularly internationally, but highlights ongoing profitability challenges from increased R&D investment. Traders will watch for sustained international growth and progress towards positive adjusted EBITDA throughout the year.
At the time of this announcement, INGN was trading at $7.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $196.5M. The 52-week trading range was $5.34 to $9.13. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.